Anaesthesia, SpinalFvMinSACSNCT07144410
Pain Control and Side Effects in Cesarean Section Anesthesia: Comparison of Intrathecal Morphine and Fentanyl
An observational study of Anaesthesia, Spinal, run by University of Oradea at 1 site in Romania.
Trial summary
Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Anaesthesia, Spinal
- What is being tested?
- fentanyl + morphine and fentanyl
- How many people
- 180 participants
- Where
- 1 siteRomania
- Study dates
- 1 Aug 2025to Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: The subjects of the study will be selected from the pregnant patients of Oradea Pelican Clinic Hospital.
Who may be able to join
- American Society of Anesthesiologists (ASA) physical status class I-II.
- Absence of significant past medical conditions.
- No documented hypersensitivity to any study drug.
- No history of chronic pain syndromes or regular analgesic consumption.
- No anxiety or depressive disorders diagnosis.
- Body weight ≥ 50 kg.
- Scheduled for elective cesarean delivery.
- Single fetus.
Who cannot join
- Patient refusal.
- Contraindication of spinal anaesthesia.
- Conversion from a natural delivery with or without an epidural anaesthesia started.
- History of substance abuse or drug dependence.
- Presence of acute or chronic fetal distress.
- Preeclampsia.
Show all 10Show fewer
- Allergic reaction occurring after enrollment.
- Refusal to receive protocol-specified analgesics or medications.
- Requirement for surgical re-intervention within 72 hours postoperatively.
- Previous administration of opioids or other central nervous system depressants prior to intervention.
Trial locations and contacts
1 site in 1 country.
Romania1 site
University of Oradea, Pelican Clinic Hospital
Oradea, Bihor County, 410505
About this study
Official title: Balancing Analgesia and Side Effects: Intrathecal Fentanyl and Morphine Versus Fentanyl for Cesarean Section Anesthesia
Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.
Read the detailed description
Eligible patients will be allocated in a 1:1 ratio into one of two groups:
Group F (Fentanyl): Hyperbaric bupivacaine 0.5% combined with fentanyl 25 µg. Group M+F (Morphine + Fentanyl): Hyperbaric bupivacaine 0.5% combined with morphine 100 µg and fentanyl 25 µg.
The dose of hyperbaric bupivacaine (7.5-11 mg) will be determined according to patient height. Randomization will be performed using the envelope technique. Two anesthetists will participate in each case: The first anesthetist will perform the spinal anesthesia and will remain blinded to the drug solution. The second anesthetist will open the allocation envelope, prepare the assigned intrathecal solution, and provide it to the first anesthetist. All drugs will be sourced from the same manufacturer to ensure uniformity.
During the pre-anesthetic visit, all patients will receive detailed information regarding the aims of the study, the planned anesthetic technique, the postoperative analgesia regimen, and the use of the Numeric Pain Rating Scale (NPS). Demographic and clinical data will be collected, including height, term weight, age, smoking status, obstetric history (gesta/para), presence of preoperative contractions, full medical history, current medications, and any allergies.
An 18G intravenous cannula will be inserted, and 500 mL of Ringer lactate will be infused prior to anesthesia. All participants will fast preoperatively and will receive pantoprazole 40 mg and metoclopramide 10 mg as premedication.
Spinal anesthesia will be performed under aseptic conditions with the patient in the sitting position at the L3-L4 interspace using a 27G Whitacre needle via a midline approach. Local infiltration with 2 mL of 1% lidocaine will precede dural puncture. The anesthetic mixture will be injected manually at a rate of 1 mL per 15 seconds with a barbotage technique.
Following injection, patients will be placed in the supine position with left uterine displacement using a roll wedge under the right hip. Warmed Ringer lactate will be administered at a rate of 10-20 mL/kg/h throughout the perioperative period. All patients will wear anti-embolic stockings on the lower limbs.
Surgery will begin once sensory block (assessed by the cold test) reaches the T4 dermatome. Non-invasive blood pressure (BP) will be measured every minute until delivery and every 3-5 minutes thereafter; heart rate (HR) and oxygen saturation (SpO₂) will be continuously monitored. A systolic BP decrease below baseline will be treated with intravenous ephedrine 5-15 mg, repeated every minute as required until BP is restored. Oxytocin 5 IU will be administered intravenously at delivery, followed by additional doses if clinically indicated. Granisetron 1 mg IV and dexamethasone 4 mg IV will be administered at the start of surgery; granisetron 1 mg will be repeated 12 hours later. Additional antiemetics will be given as required.
Postoperative analgesia will be obtained by 1 g of Paracetamol every 6 hours and Ibuprofen 400 mg every 8 hours, administered either intravenously or orally. As a reserve pain control for high intesity pain Tramadol 50-100 mg IV will be given every 6 hours as required, with a maximum daily dose of 400 mg.
Data will be recorded for the following parameters:Demographic variables as age, weight, height, smoking status, obstetric history, preoperative contractions. Time from anesthesia induction to surgical incision, time to achieve sensory block.
Pain scores will be assessed at surgical incision, at the end of surgery, and postoperatively at 4, 6, 12, 24, 48, and 72 hours, both at rest and during mobilization. Side effects such as the incidence and severity of pruritus (graded), nausea, vomiting, oversedation, dizziness, and respiratory depression. Maximum motor block using the 4-point Bromage scale, time to complete motor recovery, and sensory block level determined by the cold test.
Pain intensity will be evaluated using the Numeric Pain Rating Scale (0 = no pain; 10 = worst pain imaginable) at all scheduled postoperative time points. But for a more comprehensively comparison of the post-operative pain in the study groups, two additional assessment metrics will be employed:
- time-weighted sum pain intensity differences over 72 hours
- sum pain intensity differences area over 72 hours Descriptive statistics will include the observed frequency counts (percentage) for categorical variables; and mean ± standard deviation for numerical variables, irrespective of their distribution. Normality will be tested with the Kolmogorov-Smirnov test. For comparing means in normally distributed values, the t-test for independent samples will be applied, with Levene's test for equality of variances. For comparing distribution of non-normally distributed numerical values, the non-parametric Mann-Whitney U statistical tests will be applied and median (Inter-Quartile Range) with Tukey's hinges will be additionally provided as a descriptive statistic.
The Chi-square statistical test (either asymptotic, Fisher's exact test, or Monte-Carlo simulation with 10,000 samples) will be applied to check the statistical significance of the association between the categorical variables. The odds ratio (OR) values will be calculated for the symptoms associated with the two anesthetics, such as nausea and dizziness.
The statistical analysis will be conducted at a 95% level of confidence and a 5% level of statistical significance. All reported probability values will be two-tailed.
Statistical analysis will be performed with the statistical software IBM SPSS v. 20 and open source R v.4.0.5 packages.The study will be conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of Pelican Hospital from Oradea (no.1689/25.08.2025).
- Conditions
- Anaesthesia, Spinal
- Being tested
- fentanyl + morphine, fentanyl
- Keywords
- spinal anaesthesia, elective caesarean section, intrathecal opioids, fentanyl, morphine, opioids side effects, analgesia, fentanyl and morphine
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fentanyl + morphineDrug
Also called plus bupivacaine
The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
fentanylDrug
Also called plus bupivacaine
The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
| Study group | Role | What they receive |
|---|---|---|
| Fentanyl, Morphine and Bupivacaine | Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl, Morphine and Bupivacaine Receives: Drug: fentanyl + morphine | |
| Fentanyl and Bupivacaine | Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl and Bupivacaine Receives: Drug: fentanyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessing the perioperative analgesic efficacy
Pain intensity will be evaluated using the Numeric Pain Scale, with scores obtained at the time of skin incision, at the end of surgery, and at 4h, 6h, 12h, 24h, 48h, and 72 hours postoperatively; AUE72h (sum pain intensity differences area over 72 hours) and SPID72h (time-weighted sum pain intensity differences over 72 hours). Assessments will be conducted both at rest and during mobilization. The pain scores according to the Numeric Pain Scale will be rated between 0 and 10, meaning 0 - no pain and 10 - the worst pain imaginable
Measured: 6 months
Assessing the degree of patient's satisfaction
Assessing the degree of satisfaction on a five point scale with the highest rate as being "completely satisfied", followed by "satisfied", "so so", "unsatisfied" and "completely unsatisfied"
Measured: 6 months
Secondary outcomes (2)
Incidence of Additional Opioid-Related Adverse Effects
Other potential opioid-related adverse effects, including nausea, vomiting, dizziness, sedation, and respiratory depression, will be documented as present or absent during the first 72 postoperative hours.
Measured: 6 months
Incidence and Severity of Pruritus
Pruritus associated with intrathecal opioid administration will be recorded and graded on a 4-point scale: 0 - absent; 1 - mild; 2 - moderate; 3 - severe.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2025
- Study start1 Aug 2025
- Primary completionOct 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anaesthesia, SpinalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Oradea
- Sponsor type
- University, hospital or other
- Collaborators
- Oradea Pelican Clinic Hospital
- Responsible party
- Sponsor
- Investigators
- Aurel Mohan, MD, PhD, Study chair, Head of Surgery Department of Medicine and Pharmacy Faculty of Oradea
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07144410
- Sponsor's protocol ID
- 08FvM_Medical Study
- Acronym
- FvMinSACS
- Status last verified
- Aug 2025
- First submitted
- 14 Aug 2025
- Last updated
- 27 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Balancing Analgesia and Side Effects: Intrathecal Fentanyl and Morphine Versus Fentanyl for Cesarean Section Anesthesia
- ClinicalTrials.gov ID
- NCT07144410
- Acronym / sponsor ID
- FvMinSACS / 08FvM_Medical Study
- Conditions
- Anaesthesia, Spinal
- Keywords
- spinal anaesthesia, elective caesarean section, intrathecal opioids, fentanyl, morphine, opioids side effects, analgesia, fentanyl and morphine
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- University of OradeaUniversity, hospital or other
- Collaborators
- Oradea Pelican Clinic Hospital
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 27 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.
Detailed description
Eligible patients will be allocated in a 1:1 ratio into one of two groups:
Group F (Fentanyl): Hyperbaric bupivacaine 0.5% combined with fentanyl 25 µg. Group M+F (Morphine + Fentanyl): Hyperbaric bupivacaine 0.5% combined with morphine 100 µg and fentanyl 25 µg.
The dose of hyperbaric bupivacaine (7.5-11 mg) will be determined according to patient height. Randomization will be performed using the envelope technique. Two anesthetists will participate in each case: The first anesthetist will perform the spinal anesthesia and will remain blinded to the drug solution. The second anesthetist will open the allocation envelope, prepare the assigned intrathecal solution, and provide it to the first anesthetist. All drugs will be sourced from the same manufacturer to ensure uniformity.
During the pre-anesthetic visit, all patients will receive detailed information regarding the aims of the study, the planned anesthetic technique, the postoperative analgesia regimen, and the use of the Numeric Pain Rating Scale (NPS). Demographic and clinical data will be collected, including height, term weight, age, smoking status, obstetric history (gesta/para), presence of preoperative contractions, full medical history, current medications, and any allergies.
An 18G intravenous cannula will be inserted, and 500 mL of Ringer lactate will be infused prior to anesthesia. All participants will fast preoperatively and will receive pantoprazole 40 mg and metoclopramide 10 mg as premedication.
Spinal anesthesia will be performed under aseptic conditions with the patient in the sitting position at the L3-L4 interspace using a 27G Whitacre needle via a midline approach. Local infiltration with 2 mL of 1% lidocaine will precede dural puncture. The anesthetic mixture will be injected manually at a rate of 1 mL per 15 seconds with a barbotage technique.
Following injection, patients will be placed in the supine position with left uterine displacement using a roll wedge under the right hip. Warmed Ringer lactate will be administered at a rate of 10-20 mL/kg/h throughout the perioperative period. All patients will wear anti-embolic stockings on the lower limbs.
Surgery will begin once sensory block (assessed by the cold test) reaches the T4 dermatome. Non-invasive blood pressure (BP) will be measured every minute until delivery and every 3-5 minutes thereafter; heart rate (HR) and oxygen saturation (SpO₂) will be continuously monitored. A systolic BP decrease below baseline will be treated with intravenous ephedrine 5-15 mg, repeated every minute as required until BP is restored. Oxytocin 5 IU will be administered intravenously at delivery, followed by additional doses if clinically indicated. Granisetron 1 mg IV and dexamethasone 4 mg IV will be administered at the start of surgery; granisetron 1 mg will be repeated 12 hours later. Additional antiemetics will be given as required.
Postoperative analgesia will be obtained by 1 g of Paracetamol every 6 hours and Ibuprofen 400 mg every 8 hours, administered either intravenously or orally. As a reserve pain control for high intesity pain Tramadol 50-100 mg IV will be given every 6 hours as required, with a maximum daily dose of 400 mg.
Data will be recorded for the following parameters:Demographic variables as age, weight, height, smoking status, obstetric history, preoperative contractions. Time from anesthesia induction to surgical incision, time to achieve sensory block.
Pain scores will be assessed at surgical incision, at the end of surgery, and postoperatively at 4, 6, 12, 24, 48, and 72 hours, both at rest and during mobilization. Side effects such as the incidence and severity of pruritus (graded), nausea, vomiting, oversedation, dizziness, and respiratory depression. Maximum motor block using the 4-point Bromage scale, time to complete motor recovery, and sensory block level determined by the cold test.
Pain intensity will be evaluated using the Numeric Pain Rating Scale (0 = no pain; 10 = worst pain imaginable) at all scheduled postoperative time points. But for a more comprehensively comparison of the post-operative pain in the study groups, two additional assessment metrics will be employed:
- time-weighted sum pain intensity differences over 72 hours
- sum pain intensity differences area over 72 hours Descriptive statistics will include the observed frequency counts (percentage) for categorical variables; and mean ± standard deviation for numerical variables, irrespective of their distribution. Normality will be tested with the Kolmogorov-Smirnov test. For comparing means in normally distributed values, the t-test for independent samples will be applied, with Levene's test for equality of variances. For comparing distribution of non-normally distributed numerical values, the non-parametric Mann-Whitney U statistical tests will be applied and median (Inter-Quartile Range) with Tukey's hinges will be additionally provided as a descriptive statistic.
The Chi-square statistical test (either asymptotic, Fisher's exact test, or Monte-Carlo simulation with 10,000 samples) will be applied to check the statistical significance of the association between the categorical variables. The odds ratio (OR) values will be calculated for the symptoms associated with the two anesthetics, such as nausea and dizziness.
The statistical analysis will be conducted at a 95% level of confidence and a 5% level of statistical significance. All reported probability values will be two-tailed.
Statistical analysis will be performed with the statistical software IBM SPSS v. 20 and open source R v.4.0.5 packages.The study will be conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of Pelican Hospital from Oradea (no.1689/25.08.2025).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fentanyl, Morphine and Bupivacaine | – | Drug: fentanyl + morphinePregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl, Morphine and Bupivacaine |
| Fentanyl and Bupivacaine | – | Drug: fentanylPregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl and Bupivacaine |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The subjects of the study will be selected from the pregnant patients of Oradea Pelican Clinic Hospital.
Key inclusion criteria (8 listed)
- American Society of Anesthesiologists (ASA) physical status class I-II.
- Absence of significant past medical conditions.
- No documented hypersensitivity to any study drug.
- No history of chronic pain syndromes or regular analgesic consumption.
- No anxiety or depressive disorders diagnosis.
Key exclusion criteria (10 listed)
- Patient refusal.
- Contraindication of spinal anaesthesia.
- Conversion from a natural delivery with or without an epidural anaesthesia started.
- History of substance abuse or drug dependence.
- Presence of acute or chronic fetal distress.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fentanyl + morphineAlso: plus bupivacaineThe purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects. | Drug | Fentanyl, Morphine and Bupivacaine |
| fentanylAlso: plus bupivacaineThe purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects. | Drug | Fentanyl and Bupivacaine |
Primary outcome
Assessing the perioperative analgesic efficacy
Time frame: 6 months
Pain intensity will be evaluated using the Numeric Pain Scale, with scores obtained at the time of skin incision, at the end of surgery, and at 4h, 6h, 12h, 24h, 48h, and 72 hours postoperatively; AUE72h (sum pain intensity differences area over 72 hours) and SPID72h (time-weighted sum pain intensity differences over 72 hours). Assessments will be conducted both at rest and during mobilization. The pain scores according to the Numeric Pain Scale will be rated between 0 and 10, meaning 0 - no pain and 10 - the worst pain imaginable
Assessing the degree of patient's satisfaction
Time frame: 6 months
Assessing the degree of satisfaction on a five point scale with the highest rate as being "completely satisfied", followed by "satisfied", "so so", "unsatisfied" and "completely unsatisfied"
2 secondary outcomes
Incidence of Additional Opioid-Related Adverse Effects
Time frame: 6 months
Incidence and Severity of Pruritus
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2025.
Related trials for Anaesthesia, Spinal
RecruitingPhase 4
Norepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery
Incidence of Post-spinal Hypotension
Not yet recruiting
Comparing Spinal, Epidural, and Dural Puncture Epidural Anesthesia for Cesarean Delivery: Hemodynamics and Block Quality
Hypotension After Neuraxial Anesthesia, Cesarean Section
Enrolling by invitationObservational study
ETCO₂ Targeting and Cerebral Oxygenation
Airway Reactivity, Hemodynamic Stability During Anesthesia
Not yet recruitingPhase 4
Effects of Ondansetron Timing During Spinal Anesthesia for Urologic Surgery
Spinal Anesthesia-Induced Hypotension, Cerebral Oxygenation
RecruitingObservational study
Pupillary Light Reflex to Predict Post-Spinal Hypotension in Elective Cesarean Delivery
Hypotension, Spinal Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aurel Mohan, MD, PhD study chair
Head of Surgery Department of Medicine and Pharmacy Faculty of Oradea
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anaesthesia, Spinal, run by University of Oradea at 1 site in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessing the perioperative analgesic efficacy (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2025.